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Identification of Novel Methylation Markers in Hepatocellular 
Carcinoma using a Methylation Array
Promoter CpG island hypermethylation has become recognized as an important mechanism 
for inactivating tumor suppressor genes or tumor-related genes in human cancers of 
various tissues. Gene inactivation in association with promoter CpG island hypermethylation 
has been reported to be four times more frequent than genetic changes in human 
colorectal cancers. Hepatocellular carcinoma is also one of the human cancer types in 
which aberrant promoter CpG island hypermethylation is frequently found. However, the 
number of genes identified to date as hypermethylated for hepatocellular carcinoma (HCC) 
is fewer than that for colorectal cancer or gastric cancer, which can be attributed to fewer 
attempts to perform genome-wide methylation profiling for HCC. In the present study, we 
used bead-array technology and coupled methylation-specific PCR to identify new genes 
showing cancer-specific methylation in HCC. Twenty-four new genes have been identified 
as hypermethylated at their promoter CpG island loci in a cancer-specific manner. Of these, 
TNFRSF10C, HOXA9, NPY, and IRF5 were frequently hypermethylated in hepatocellular 
carcinoma tissue samples and their methylation was found to be closely associated with 
inactivation of gene expression. Further study will be required to elucidate the 
clinicopathological implications of these newly found DNA methylation markers in 
hepatocellular carcinoma. 
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INTRODUCTION 
A CpG island is an approximately 1-kb DNA sequence with a 
high density of CpG dinucleotides. About 70% of human genes 
are known to harbor CpG islands in their promoter sequences 
(1, 2). In normal cells, promoter CpG islands are usually pro-
tected from aberrant hypermethylation, except for those on im-
printing genes or genes of inactivated X chromosomes (3, 4). 
However, in association with carcinogenesis, hundreds of pro-
moter CpG islands undergo aberrant hypermethylation, which 
represses gene transcription of active genes or enforces suppres-
sion of already inactive genes (5). Promoter CpG island hyper-
methylation has become recognized as an important mecha-
nism for inactivation of tumor suppressor genes or tumor-relat-
ed genes in human cancers, and occurs in virtually all types of 
human cancers (6). In addition to gene inactivation, promoter 
CpG island hypermethylation has received attention for its poten-
tial utility as a biomarker for tumor detection or prediction of 
prognosis or response of tumor cells to chemotherapeutic agents 
(7). Hepatocellular carcinoma (HCC) is one of the human cancers 
in which researchers are actively studying epigenetic changes. 
More than 113 genes have been found to be hypermethylated 
in HCC in a cancer-specific manner and some of them have been 
demonstrated to have a close association between hypermeth-
ylation and poor prognosis for HCC patients, supporting the po-
tential usefulness of DNA methylation markers as prognostic 
markers (8-10).
  However, the number of genes that have been identified to 
date as harboring hypermethylation in their promoter CpG is-
land loci is far fewer for HCC than for colon cancer or gastric 
cancer, which can be attributed to fewer attempts to perform 
genome-wide methylation analysis compared with colon can-
cer or gastric cancer. Considering that about 400 genes may be 
inactivated through promoter CpG island hypermethylation in 
colorectal cancers (11), there remain many genes that may be 
hypermethylated in HCC.
  Among the various technologies available for large-scale anal-
ysis of DNA methylation, the GoldenGate methylation solution 
is a powerful and accurate screening tool for analyzing methyl-
ation status in 807 genes (12). With the advent of this technique, 
we were able to analyze the methylation status of 687 promoter 
CpG island loci in liver cancer. The aim of the present study was 
to identify additional genes that are hypermethylated in HCC in 
a cancer-specific manner that have not yet been reported as such 
in the literature thus far. Shin SH, et al.  •  New DNA Methylation Markers in Hepatocellular Carcinoma
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MATERIALS AND METHODS
Cell lines and 5-aza-dC treatment
We used eight different human HCC cell lines (SNU398, SNU475, 
SNU739, SNU761, SNU878, SNU886, HepG2, and Huh7) ob-
tained from the Korean Cell Line Bank (Seoul, Korea). All of the 
cell lines except Huh7 were grown in RPMI-1640 medium sup-
plemented with 10% fetal bovine serum. Huh7 was grown in 
DMEM medium supplemented with 10% fetal bovine serum. 
All cell lines were cultured in a humidified 37°C, 5% CO2 incu-
bator. The cell lines were seeded at 3×10
5/mL in their respective 
culture media and treated with 1 µM and 5 µM 5-aza-dC (Sigma 
Chemical Co., St. Louis, MO, USA) for 96 hr; media and drugs 
were replaced every 24 hr. As a control, cell lines were mock-treat-
ed in parallel with the addition of an equal volume of PBS with-
out the drug. We prepared total RNA using the RNeasy Mini kit 
(Qiagen, Valencia, CA, USA).
Tissue samples
Fresh-frozen samples of HCC and paired non-neoplastic liver 
tissues were obtained from patients (n=5) who underwent cu-
rative resection for HCC at the Seoul National University Hospi-
tal in 2008. In addition, after microscopic examination of HCC 
samples from patients who underwent curative resection at the 
Seoul National University Hospital from 2001 to 2002, we select-
ed 50 cases of HCC that had sufficient amounts of archival neo-
plastic and non-neoplastic tissues for the DNA methylation 
study. For the bead array study requiring fresh tissue samples, 
we obtained informed consent from the patients. The Institu-
tional Review Board approved this study. 
Methylation microarray
DNA methylation analysis of individual genes was performed 
using GoldenGate Methylation Solution utilizing the current 
Cancer Panel I platform (Illumina, San Diego, CA, USA), which 
probes 1,505 CpG loci selected from 807 genes. Using this meth-
od, oligonucleotide primers query putative methylation sites in 
Table 1. Primers for methylation-specific polymerase chain reaction
Gene Forward primer  Reverse primer Tm (°C) Product (bp)
ADAMTS12 TTTATTTTATATTTCGTCGAAAGCG ACGACTACAAAACTACCCGCG 61 135
ADCYAP1 GGTTTGGTTAGTTATTGGGCGTC CCCTAAATTAAACAACACTTAACGACAACCG 59 118
CTSL TTTGGGATAGTTAGTAAATAAGTTACGAATCGC AACTCTACTTCTAAAACCTCGAATCTAAATTCG 57 150
DST TTTTTTAGTAGGGGGTTGCGTATAGC CCGAATCCCCAAAAACGACG 59 103
F2R TTTTTATATTTTAGGAGGGTCGAGAC TTCCTCTAAACACCGTTAATTCG 60 124
FGF3 GGAGTTTTTTTGTCGTCGTTTTTCGC CGCCGCCGATAACTAATATCCG 59 116
FLT3 GGAGTTTCGGGGGTCGTC CCCCAAAAACAAAAACCGAAACGAAAACG 59 134
FLT4 CGTATTGTTCGGGTGTATCGGAC AAACGAAAACCGAAAACGAACCCG 59 105
FZD9 CGGGCGGATATTTATTAGGTTCGGTTTTATTTC CCCCCGAAACGAAACTCCG 60 123
GP1BB TAGCGGGTGTTCGAGTGTTTC CTAACCAAAAATAACCCAAAAACCGCG 59 138
HIC2 GTTTGGGTTTTCGGTTTTTTTCGC CGAAACCTACGAAAACGAAACCG 59 115
HOXA9 CGGGCGTTTTTCGTTTTAGGC AAATCCGTCCCAAACGAAACCG 60 122
HS3ST2 GGGAGCGTTCGAGTCGTTC CACAATACCAAAAAATCCCGAAAACAACG 59 117
ICA1 GTCGTTGCGTTGCGTTGC ACGTCAACGTCAACCGAAAACG 59 130
IGF2AS CGGTTGCGTCGGGTC TAAACGCACCCCGATAAACTCG 59 131
IHH TTATTCGGACGTTTGAGTTTTCGTAGC GAACGAAAAACATAACCGAAAAACCCG 59 111
IRAK3 CGTGTTTTTAGGGTTTTGTTGTCGTC CGAACCCCGAAAACGAAACG 59 108
IRF5 AATTGAGTATTGTAGCGGGAGGTAC  CTCCAAAAAAATACCAAACGACG 61 116
MCM2 TTTGAGTTTGTGATTCGTTTATTTC CCGACGACACTTACTAACTACGTA 58 139
MLF1 TTGTTAGGGTAGCGGCGTATTGTTTTTC AAACGATACCCGCCGAAATAAAAAATACG 60 113
NGFR TAGTTAGAGCGAGTCGAGTCGC CTCGACTTCCAACTCGATCCG 60 109
NOTCH3 GGTAGGGATTTCGGGAGGTC GCCAACTTCGCCGAAATAAAACG 59 120
NPY AAAGAAGGAAAGTAGGGATCGGGTATTGTTC CTAAAACCGCGTAAACGAAACAACG 59 120
PDGFRB TTATATTTTGAGCGAACGGGC AAACAAAAAAAATAAACGCGTACGT 62 139
PGF CGGGTTGATCGGGCGTTTC GCGCCTAAATTTCAAAAACTAAACCGAAACG 61 103
PLAGL1 GCGGCGATGATAAGAGTTTCGC GACCCCAACCGACCCG 61 107
PTCH2 GTAGTTGTTATTTCGAGTTTTGTTGTGCGTTTC CGCTCCGTAAACCGTAAACCG 59 134
RBP1 GATTTTTTCGTAGGTTTTGTGCG    ACCGATACTACGCGAATAATAAACG    59 114
SH3BP2 TTTCGGGATTCGGGTCGC CCCCCAAAAAACGCGTAAACG 60 108
TAL1 ATTTGGTTGAGGAGGTAATCGC CCGACAAACTATCTAAAACATTTTCG 62 108
TESK2 GTAGGCGTTTTAGTTTTTCGCGGTTC TACCATAACCCCACAATCGAAACCG 62 134
TIAM1 TTTTTTACGGGTTTTCGCGGTTC GACGCTACTCTACCGACCG 59 110
TNFRSF10C TAAGGGGTGAAGGAGCGTTTTTTATC ACGCCGTCCTAAATCCTAAATCG 59 104
WNT2 TTAGGCGTAGTATTTTTTTTTTCGGTTGCGTTC CCAATTCCCCAAACGCAACG 59 115
ZP3 GGGTTCGTCGTTTTCGTAGTGTAC TCAACTAAACTACGAAACGACCATAACCG 59 106Shin SH, et al.  •  New DNA Methylation Markers in Hepatocellular Carcinoma
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bisulfite-converted genomic DNA. Bisulfite modification of ge-
nomic DNA was performed using the EZ DNA methylation kit 
(Zymo Research, Orange, CA, USA). Similar to methylation-spe-
cific PCR, two primer sets are designed for each CpG target; one 
primer set corresponds to the unmethylated, bisulfite-convert-
ed sequence (uracil) while the other corresponds to the uncon-
verted sequence (5-methyl cytosine). The methylation level (beta 
value) is determined by the ratio of the fluorescent signals from 
methylated and unmethylated alleles. The beta value identifies 
the level of DNA methylation at a CpG site, ranging from 0 in the 
case of almost all unmethylated sites to 1 for completely meth-
ylated sites (12). Of 1,505 CpG sites (selected from 807 genes) 
included in GoldenGate Methylation Cancer Panel I, 1,044 of 
the CpG sites are located within CpG islands, and 461 are locat-
ed outside of CpG islands. Comparing the average beta values 
for the 1,044 CpG sites between HCC and non-neoplastic liver 
tissues, cancer-specific hypermethylation was determined to 
be present when the average beta value for a CpG site was sig-
nificantly greater (P<0.05) for the HCC samples (n=5) than for 
the non-neoplastic liver tissues (n=5). 
Methylation-specific polymerase (MSP) chain reaction
For MSP analysis, DNA was extracted following a standard phe-
nol-chloroform extraction method. Bisulfite modification of ge-
nomic DNA was carried out using the EZ DNA methylation Kit 
(Zymo Research). Primers were designed using two web sites, 
MSPPrimer (http://www.mspprimer.org) and MethPrimer (http: 
//www.urogene.org/methprimer). Primer sequences and PCR 
conditions are shown in Table 1. MSP was performed as previ-
ously described (13). 
Quantitative RT-PCR
Total RNA was prepared using the RNeasy (Qiagen) kit accord-
ing to the manufacturer’s protocols. A total of 5 μg of RNA was 
reverse transcribed using Oligo dT and Superscript III (Invitro-
gen, Carlsbad, CA, USA). Quantitative RT-PCR amplification 
reactions were performed using the SYBR
® Green PCR Master 
Mix (Applied Biosystems, Foster City, CA, USA) with a 7300 Re-
al-Time PCR System (Applied Biosystems). The expression lev-
els of the genes were normalized to the expression of GAPDH. 
Primer sequences and PCR conditions are shown in Table 2.
RESULTS
Microarray analysis of methylated genes
The methylation profiles of five pairs of HCC and non-neoplas-
tic liver tissues were analyzed for 807 genes using the Illumina 
GoldenGate Methylation Solution. In total, 72 annotated genes 
(81 CpG sites) were found to be hypermethylated in tumor tis-
sues. After excluding genes without a CpG island in the promoter 
(18 genes), imprinted genes (2 genes), and genes for which meth-
ylation of their promoter CpG island loci has already been report-
ed for HCC (17 genes), we explored DNA hypermethylation for 
the remaining 36 genes using MSP. These 36 genes were consid-
Table 2. Primers for quantitative RT-PCR
Gene Forward primer  Reverse primer Tm (°C) Product (bp)
ADAMTS12 TGCAATTCACATTGTTGTGG GTGAGGCTGACACATTCCTG 59 253
ADCYAP1 GATCTTCACGGACAGCTA AG  GTTTGGATAGAACACACGAGC 60 226
DST AGCAAAGGACGCATACTGAC ATTTGGCTCTACTCCTGAAC 56 270
FGF3 TTGGAGATAACGGCAGTGGA  CTCCAGGTTATCCGGGCTCT 56 448
FLT3 GAGGACTTGAATGTGCTTACA TCCCACAGTAATATTCCATATGA 55 308
FZD9 TGCCCCTCTCTGGCTACCTG  GGGCACCGTGTAGAGGATGG  62 164
GAPDH  CAATGACCCCTTCATTGACC TGGAAGATGGTGATGGGATT 55 135
GP1BB CCTGCAAACTCGACAGGAC CAGAGTTTGGAAGGGAGACG 59 231
HIC2 TGCGAGAAGACCTACAAGGA AGCTGGCACTCGTAAGGTTT 59 251
HOXA9 GCGCCTTCTCTGAAAACAAT CCAGATCTTGACCTGCCTCT 60 242
HS3ST2 GGATTCCCTTGCTTGAAAAA TGCAACTCAAGTTGGGAAAG 59 302
IRAK3 TTTGAATGCAGCCAGTCTGA GCATTGCTTATGGAGCCAAT 59 365
IRF5 CAGGGAGCTTCTCTCTGAGG AAGAGTTCCACCTGCTCCTG 68 237
MLF1 GGTTTTTCAGGCCTCAACTC AAACCTCACTTTGCCACTCC 64 245
NOTCH3 TGTGGACGAGTGCTCTATCG AATGTCCACCTCGCAATAGG 60 238
NPY AACCTCATCACCAGGCAGAG CTGCATGCATTGGTAGGATG 60 220
PDGFRB GGGCTAGACACGGGAGAATA GATCATAGGGGACAGGCAGT 59 250
PTCH2 GTGGCAAAGTGCTCTTTCTG TCCCAGGACTTCCCATAGAG 55 301
RBP1 GTTGGGAAGGAGTTTGAGGA GCTCACACATCCTGCTGATT 59 258
SH3BP2 ATCCACATCAGCAAGAAGCA GAGTCATCCTCATCGTCGTG 68 251
TAL1 AAGAGGAGACCTTCCCCCTA CCTCCTCCTCCTGGTCATT 66 247
TIAM1 AAGACGTACTCAGGCCATGTCC GACCCAAATGTCGCAGTCAG 61 252
TNFRSF10C GATTACACCAACGCTTCCAA TTGGCACCAAATTCTTCAAC 59 248
WNT2 CAGACGCAAGGGGGTTAATA CACATCTGGATGTCGGTGAC 61 202
ZP3 CAGAATGCCTCCCCTTATCA ATCTGGGTCCTGCTCAGCTA 60 210Shin SH, et al.  •  New DNA Methylation Markers in Hepatocellular Carcinoma
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ered to be potential novel methylation markers for HCC. This 
gene filtering approach is depicted in Fig. 1. 
Validation of the methylation status of candidate genes in 
the HCC cell lines using MSP 
For MSP analysis, we attempted to design primers for the 36 genes 
using both MSPPrimer (http://www.mspprimer.org) and Meth- 
Primer (http://www.urogene.org/methprimer). However, for 
one gene (HOXB2), neither tool was able to design primers, be-
cause it has a short CpG island in the promoter. Therefore, we 
examined the methylation status of the remaining 35 genes in 
the 8 HCC cell lines. It was found that 26 of the genes (HOXA9, 
TNFRSF10C, NPY, TIAM1, PDGFRB, IRAK3, SH3BP2, IRF5, 
HIC2, TAL1, HS3ST2, MLF1, IGF2AS, ADCYAP1, FGF3, WNT2, 
ADAMTS12, FLT3, PTCH2, GP1BB, RBP1, FZD9, DST, NOTCH3, 
PLAGL1, and ZP3) were methylated in at least one HCC cell line 
(26 of 35; 74.3%). The remaining 9 genes (TESK2, IHH, MCM2, 
CTSL, F2R, PGF, NGFR, FLT4, and ICA1) were not found to be 
methylated in the HCC cell lines using the MSP assay (Figs. 2, 3).
 
Confirmation of hypermethylation of newly developed 
candidate genes in liver tissues
To determine whether the genes that were hypermethylated in 
the HCC cell lines were hypermethylated in a cancer-specific 
manner, we analyzed the methylation status of the 26 genes in 
18 normal liver samples and 50 primary HCC samples using 
methylation-specific PCR. Of the candidate 26 genes that showed 
methylation in the cell lines, promoter methylation was detect-
ed in 25 of the genes in primary tumor tissues. In contrast, only 
five genes (5 of 26; 19.2%) were methylated in normal tissues. 
Moreover, all but one of these genes (IGF2AS) were methylated 
at low frequencies in the non-neoplastic liver tissues (Fig. 4). 
807
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Fig. 1. Flow chart for selection of candidate methylation markers. We used 5 paired 
hepatocellular carcinoma/normal tissues to screen for candidate methylation markers 
using a methylation array. We obtained 72 candidates that showed significant hyper- 
methylation in hepatocellular carcinoma tissues. We removed genes with no CpG 
island loci in their promoters, imprinted genes, and genes for which methylation status 
was already known for hepatocellular carcinoma. Thus, we selected 36 genes to further 
examine for methylation analysis using methylation-specific PCR.
Fig. 2. Representative examples of MSP analysis of DST, FLT3, PTCH2 and TIAM1 in 
8 HCC cell lines. DNA extracted from 8 HCC cell lines were amplified with primers 
specific to the methylated (M) or unmethylated (UM) CpG islands of each gene after 
modification with sodium bisulfite. +, positive control; DW, distilled water. Positive 
controls for methylated MSP and unmethylated DNA are M.SssI-treated placental 
DNA and whole-genome amplified DNA, respectively.
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Fig. 3. Summary of methylation-specific PCR for 
hepatocellular carcinoma (HCC) cell lines. We exa- 
mined eight HCC cell lines for methylation status 
of the 35 genes and found that 26 of the genes 
(HOXA9, TNFRSF10C, NPY, TIAM1, PDGFRB, IRAK3, 
SH3BP2, IRF5, HIC2, TAL1, HS3ST2, MLF1, IGF2AS, 
ADCYAP1, FGF3, WNT2, ADAMTS12, FLT3, PTCH2, 
GP1BB, RBP1, FZD9, DST, NOTCH3, PLAGL1, and 
ZP3) were methylated in at least one HCC cell line. 
Data are color-coded as follows: gray fill indicates 
the presence of methylation, whereas white fill 
indicates the absence of methylation.
Fig. 4. Summary of methy- 
lation-specific PCR results 
in hepatocellular carcinoma 
(n=50) and non-neoplastic 
liver tissue samples (n=18). 
Out of 26 genes showing 
methylation in HCC cell 
lines, promoter methylation 
was detected in 25 genes 
in primary tumor tissues. 
Data are color-coded as 
follows: gray fill indicates 
the presence of methy- 
lation, while white fill indi- 
cates absence of methy- 
lation.
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Thus, the vast majority of the genes were found to show cancer-
specific methylation at frequencies of 6%–98% (Fig. 5). Thus, 24 
new cancer-specific CpG island loci were identified through 
our approach (Table 3). 
Gene expression and induction after 5-aza-dC treatment 
in HCC cell lines
For hypermethylated and transcriptionally silenced genes, the 
DNA demethylating agent 5-aza-dC is known to induce gene 
re-expression (14, 15). To identify whether promoter CpG island 
hypermethylation was closely associated with gene expression 
in the 24 newly identified cancer-specific methylated genes, we 
treated the 8 HCC cell lines with 5-aza-dC (1 and 5 µM for 96 hr) 
and performed quantitative RT-PCR of the mock-treated and 
5-aza-dC treated cell lines. TNFRSF10C, NPY, TIAM1, and HOXA9 
were methylated in all cell lines and showed up-regulation of 
mRNA expression in all cell lines with 5-aza-dC, although TIAM1 
was not re-expressed in two cell lines, SNU-878 and Huh7. Most 
of the methylated genes exhibited re-expression after 5-aza-dC 
treatment; in contrast, SNU-886 in PDGFRB; SNU-878 in IRF5; 
SNU-398, HepG2, and Huh7 in HIC2; HepG2 and Huh7 in 
HS3ST2; SNU-878 in ADCYAP1; and SNU-886 in NOTCH3 were 
Table 3. New cancer-specific methylated genes 
Genes  Gene name Loci Function
ADAMTS12 ADAM metallopeptidase with thrombospondin type 1 motif, 12 5q35 Metal ion binding, metalloendopeptidase activity, zinc ion binding
ADCYAP1 Adenylate cyclase activating polypeptide 1 18p11 Hormone activity, neuropeptide hormone activity
DST Dystonin isoform 1eB  6p12–p11 Actin binding, calcium ion binding, integrin binding, protein binding 
FGF3 Fibroblast growth factor 3  11q13 Growth factor activity, protein binding
FLT3 Fms-related tyrosine kinase 3 13q12 ATP binding, nucleotide binding, receptor activity
FZD9 Frizzled 9 7q11.23 G-protein coupled receptor activity, Wnt receptor activity
GP1BB Glycoprotein Ib (platelet), beta polypeptide 22q11.21 Protein binding, transmembrane receptor activity
HIC2 Hypermethylated in cancer 2 22q11.21 DNA binding, metal ion binding
HOXA9 Homeobox protein A9 isoform b 7p15–p14 Protein binding, sequence-specific DNA binding, transcription factor activity
HS3ST2 Heparan sulfate D-glucosaminyl 3-O-sulfotransferase 2 16p12 Sulfotransferase activity, transferase activity
IRAK3 Interleukin-1 receptor-associated kinase 3 12q14.3 ATP binding, identical protein binding, magnesium ion binding
IRF5 Interferon regulatory factor 5 isoform b 7q32 RNA polymerase III transcription factor activity
MLF1 Myeloid leukemia factor 1 3q25.1 Protein binding, protein domain specific binding
NOTCH3 Notch homolog 3 19p13.2–p13.1 Calcium ion binding, receptor activity
NPY Neuropeptide Y 7p15.1 Calcium channel regulator activity, neuropeptide hormone activity
PDGFRB Platelet-derived growth factor receptor beta  5q31–q32 ATP binding, nucleotide binding, platelet activating factor receptor activity; 
protein binding; 
PTCH2 Patched 2 1p33–p34 Hedgehog receptor activity
RBP1 Retinol binding protein 1 3q23 Lipid binding, retinal binding, retinol binding
SH3BP2 SH3-domain binding protein 2 4p16.3 SH3/SH2 adaptor activity
TAL1 T-cell acute lymphocytic leukemia 1 1p32 DNA binding, transcription regulator activity
TIAM1 T-cell lymphoma invasion and metastasis 1 21q22.11 Rho guanyl-nucleotide exchange factor activity
TNFRSF10C Tumor necrosis factor receptor superfamily, member 10c  8p22–p21 GPI anchor binding, transmembrane receptor activity
WNT2 Wingless-type MMTV integration site family member 2  7q31 Extracellular matrix structural constituent, signal transducer activity
ZP3 Similar to Zona pellucida sperm-binding protein 3  7q11.23 Acrosin binding, receptor activity
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down-regulated by 5-aza-dC. In addition, HepG2 and SNU-761 
in WNT2, HepG2 in ADAMTS12, and SNU-878 in FLT3 were 
not re-expressed (Fig. 6). In such cases, histone modification 
may be related to transcription suppression (16, 17). 
 
DISCUSSION
Although many studies have reported aberrant hypermethylation 
of genes in HCC, for example, identifying E-cadherin, RASSF1A, 
GSTP, SOCS1, SFRP1, and PTEN as tumor suppressor gene si-
lenced by hypermethylation, most of these studies were limited 
to analysis of a single or a few specific genes (8-10). Therefore, 
the true extent of promoter CpG island hypermethylation in HCC 
remains largely unknown. With advancements in microarray 
technology, the number of genes found to be hypermethylated 
in HCC in a cancer-specific manner is expected to increase ex-
ponentially, leading to a better understanding of epigenetic 
modulation of tumor-related genes in hepatocarcinogenesis. 
The GoldenGate bead-array technology incorporates a strong 
analytical methylation platform and provides reliable and high-
ly reproducible data (12). Here, we present identification of new 
genes demonstrating cancer-specific methylation in HCC through 
the use of bead-array technology. The fidelity of the bead-array 
results was confirmed using methylation-specific PCR for genes 
selected according to our criteria (Fig. 1). As a result of the pres-
ent approach, 24 genes were newly identified as cancer-specific 
methylation loci for HCC. 
  Table 3 summarizes the functions of the genes that were new-
ly identified to be hypermethylated in a cancer-specific manner 
in HCC. TNFRSF10C, HOXA9, NPY, and IRF5 were frequently 
methylated in our panel of cell lines and HCC tissues and their 
methylation was correlated with low expression levels or silenc-
IRAK3
TNFRSF10C
SH3BP2 IRF5
NPY TIAM1
HIC2 TAL1
HS3ST2
ADAMTS12 FLT3  PTCH2 GP1BB RBP1
FZD9 DST NOTCH3 ZP3
MLF1 ADCYAP1 FGF3 WNT2
PDGFRB HOXA9
PBS
1 µm 5-aza-DC
5 µm 5-aza-DC
Fig. 6. Analysis of mRNA expression of candidate genes in hepatocellular carcinoma cell lines by quantitative RT-PCR. Cells were either mock-treated (PBS) or treated with 
5-aza-dC (1AZA [1 μM] or 5AZA [5 μM] for 96 hr) as indicated. The expression patterns and re-expression patterns for each gene after 5-aza-dC treatment are shown for the 
cell lines that were methylated. Numbers along the horizontal axis indicate the cell lines. Gene expression levels were determined by quantitative RT-PCR and normalized to 
GAPDH levels. 
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ing. These genes were re-expressed in the majority of the cell 
lines after 5-aza-dC treatment. Therefore, these genes are con-
sidered to be repressed by DNA hypermethylation in their pro-
moter CpG islands. Although it is unclear whether TNFRSF10C 
plays a pro-apoptotic role or an anti-apoptotic role in tumors, 
hypermethylation of TNFRSF10C has been reported in various 
human cancers, including breast, lung, prostate, and neuroblas-
tomas (18). HOXA9 encodes a DNA-binding transcription fac-
tor that may regulate gene expression, morphogenesis, and dif-
ferentiation. Expression of HOXA9 proteins is spatially and tem-
porally regulated during embryonic development (19). HOXA9 
promoter CpG island methylation has been reported in ovary 
and lung cancer (20, 21). NPY is involved in cell motion and cell 
proliferation as well as neuropeptide hormone activity (22, 23). 
In prostate cancer, low NPY expression is closely associated with 
aggressive clinical behavior (24). In another recent study, NPY 
was shown to be frequently methylated in neuroblastomas (25). 
IRF5, a member of the interferon regulatory factor family, is known 
to be related to innate immune system activity and is also a crit-
ical regulator of DNA damage-induced apoptosis (26). Because 
IRF5 is critical for induction of apoptosis, IRF5 deficiency pre-
disposes cells to tumorigenic transformation (27). However, 
methylation of IRF5 in cancer has rarely been reported.
  Recently, the role of chromatin structure and epigenetic alter-
ations in controlling gene transcriptional activity during embry-
onic stem (ES) cell self-renewal and differentiation has been in-
tensively investigated (28, 29). Recent studies have attempted 
to identify the relationships between DNA methylation, histone 
modifications, and promoter occupancy of pluripotent regula-
tors such as PcG in regulation gene expression in ES cells (30). 
Gene promoter chromatin patterns, including PcG-mediated 
repressive histone modifications, may render certain genes vul-
nerable to DNA hypermethylation. These changes may enhance 
the likelihood of tumor initiation and progression from cell trans-
formation (30). To identify whether polycomb repressive com-
plex 2 (PRC2) occupancy information obtained from embryonic 
stem cells may predict the vulnerability of individual CpG island 
loci to hypermethylation, we compared the average methylation 
level (beta value) of each CpG island locus between normal tis-
sues and tumor tissues and correlated it with PRC2 occupancy. 
In PRC2-positive CpG islands, the methylation level of the tumor 
group was higher than the methylation level of the normal group. 
In addition, the differences between the two groups were larger 
when the CpG island loci were occupied by two or more com-
ponents of the PRC2 complex. However, there were no differ-
ences among PRC2-negative CpG islands (Supplementary Table 
1). Thus, PRC2 may indicate that these genes are preferred sub-
strates for targeted methylation. 
  In addition to hypermethylation of promoter CpG island loci, 
some hypomethylated CpG sites were also identified through 
comparison of methylation levels (bead array-determined beta 
values) of CpG sites in HCC. CpG sites showing hypomethyl-
ation in a cancer-related manner appear to be different from 
those that were hypermethylated with respect to their relation-
ships with CpG island loci. In the present study, we found that 
69 genes (83 CpG sites) were significantly hypomethylated in 
tumor tissues. Of these 83 CpG sites, only 23 sites (27.7%) were 
located in promoter CpG island loci, in contrast with the 63 of 
81 (77.8%) hypermethylated CpG sites that were located in CpG 
island loci (Supplementary Table 2). The identified hypometh-
ylated genes tend to be involved in biological processes of im-
munity, neuronal activity, lipid metabolism, and transport, where-
as the hypermethylated genes tend to be involved in nucleic 
acid metabolism, cell proliferation, differentiation, and the cell 
cycle. For example, IL16, involved in chemokine-mediated im-
munity, was significantly hypomethylated in HCC compared to 
non-neoplastic liver tissues (P=0.003). GABRA5, with neurotrans-
mitter receptor activity, was hypomethylated (P<0.001). APOC1, 
which processes lipid metabolism and transport, was hypometh-
ylated (P=0.001). In addition, certain oncogenes, including HGF, 
BLK, and PGR were hypomethylated in HCC. Interestingly, hy-
pomethylation of histone deacetylase 1 (HDAC1), which plays 
a key role in the regulation of eukaryotic gene repression, was 
prominent and had the largest significant difference in methyl-
ation levels between HCC and non-neoplastic liver tissues (P< 
0.001).
Supplementary  Table 1. The average methylation level (beta value) of each CpG 
island locus between non-neoplastic tissues and HCC and correlated it with polycomb 
repressive complex 2 (PRC2) occupancy. The value of PRC2 occupancy represents 
the number of occupied components of PRC2 in the gene promoter
The number  
of genes
Beta value (mean)
Non-neoplastic 
liver
HCC
PRC2 occupancy=0 407 0.326  0.348 
PRC2 occupancy= >1 132 0.244  0.315 
PRC2 occupancy=1   41 0.245  0.277 
PRC2 occupancy=2   34 0.231  0.319 
PRC2 occupancy=3   57 0.253  0.339
Supplementary  Table 2. The summarization of the number of CpG sites undergoing 
hypermethylation or hypomethylation in association with cancerization according to 
their genomic location. CpG sites located in CpG island loci tend to undergo hyperme-
thylation in association with cancerization whereas CpG sites located in non-CpG 
island tend to become hypomethylated
Hypermethylation Hypomethylation
Promoter
   CpG island
   Non-CpG island
39
15
19
38
First exon
   CpG island
   Non-CpG island
17
  3
  4
17
Second or distal exon or intron
   CpG island
   Non-CpG island
  7
  0
  0
  5
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  In summary, we have identified 24 novel cancer-specific meth-
ylation markers for HCC using array-based methylation profil-
ing and coupled MSP. Of these, TNFRSF10C, HOXA9, NPY, and 
IRF5 were frequently hypermethylated in HCC tissues and their 
promoter hypermethylation was correlated with inactivation of 
gene expression in cell lines. The clinicopathologic implications 
of these newly identified DNA methylation markers will need to 
be further investigated in large-scale studies of HCC samples. 
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